blisibimod
AN-SLE3331
Phase 3 small_molecule completed
Quick answer
blisibimod for Systemic Lupus Erythematosus is a Phase 3 program (small_molecule) at Santhera Pharmaceuticals (Deutschland) GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Santhera Pharmaceuticals (Deutschland) GmbH
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed